PRKAA1 and leukemia: To measure AMPK’s necessity in antitumor immunity, 1 × 106 fl/fl or AMPK-dKO donor T cells were transplanted with T cell–depleted (TCD) BM and a lethal dose of GFP+ p815 leukemia cells into irradiated B6D2F1 recipients.